Quinolone Antibacterials - An Update of their Pharmacology and Therapeutic Use

Drugs

Volumn 47, Issue 6, 1994, Pages 872-901

  von Rosenstiel, Niels ^a   Adam, Dieter ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTACID AGENT; CIPROFLOXACIN; ENOXACIN; FENBUFEN; FLEROXACIN; LOMEFLOXACIN; METHYLXANTHINE; NONSTEROID ANTIINFLAMMATORY AGENT; NORFLOXACIN; OFLOXACIN; PEFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SPARFLOXACIN; THEOPHYLLINE; TOSUFLOXACIN; WARFARIN;

ARTHROPATHY; BACTEREMIA; BACTERICIDAL ACTIVITY; BLOOD TOXICITY; BONE INFECTION; CARDIOVASCULAR DISEASE; CENTRAL NERVOUS SYSTEM DISEASE; CENTRAL NERVOUS SYSTEM INFECTION; CLINICAL TRIAL; CYSTIC FIBROSIS; EYE TOXICITY; GASTROINTESTINAL DISEASE; GASTROINTESTINAL INFECTION; HEPATOBILIARY DISEASE; HUMAN; HYPERSENSITIVITY; INFECTIOUS ARTHRITIS; KIDNEY DISEASE; LIVER DISEASE; MALE GENITAL SYSTEM; MUTAGENICITY; ORAL DRUG ADMINISTRATION; POSTANTIBIOTIC EFFECT; RESPIRATORY TRACT INFECTION; REVIEW; SEPTICEMIA; SEXUALLY TRANSMITTED DISEASE; SKIN INFECTION; SOFT TISSUE INFECTION; TERATOGENICITY; URINARY TRACT DISEASE; URINARY TRACT INFECTION;

ANIMAL; ANTI-INFECTIVE AGENTS, QUINOLONE; BACTERIAL INFECTIONS; BIOLOGICAL AVAILABILITY; DNA, BACTERIAL; DRUG INTERACTIONS; DRUG RESISTANCE, MICROBIAL; GRAM-NEGATIVE BACTERIA; GRAM-POSITIVE BACTERIA; HALF-LIFE; HUMAN; INTESTINAL ABSORPTION; MICROBIAL SENSITIVITY TESTS; TISSUE DISTRIBUTION;

BACTERIA (MICROORGANISMS); CHLAMYDIA; LEGIONELLA; MYCOBACTERIUM; MYCOPLASMA; NEGIBACTERIA; POSIBACTERIA;

EID: 0028223448     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.2165/00003495-199447060-00003     Document Type: Review

References (107)

1. The clinical problems of bacterial resistance to the new quinolones
2. Use of quinolones in treatment of prostatitis and lower urinary tract infections
3. Bacterial skin and soft tissue infections
4. Quinolones in neonates
5. Quinolones in the treatment of uncomplicated urinary tract infections
6. Morphologic and biochemical changes in articular cartilage of immature Beagle dogs with difloxacin
7. Killing kinetics of four quinolones against gram-positive cocci
8. Quinolones in animal models of infection
9. Quinolones in children with invasive salmonellosis
10. Quinolones for the urinary tract
11. Quinolones in acute bacterial exacerbations of chronic bronchitis
12. Toxicity of the quinolones
13. How safe is ciprofloxacin in pediatrics: worldwide clinical experience based on compassionate use
14. Antimicrobial therapy in the immunocompromised host
15. The clinical experience of ofloxacin in the treatment of sexually transmitted diseases
16. Biphasic kinetics of bacterial killing by quinolones
17. Repeated use of ciprofloxacin in pediatric cystic fibrosis population
18. Fluoroquinolone resistance in the hospital versus outpatient setting
19. Mode of action of quinolones: biochemical aspects
20. Economic impact of oral ciprofloxacin following standard intravenous therapy
21. Multicenter evaluation of the in vitro activities of three new quinolones, Sparfloxacin, (CJ-960) and PD 131,628, compared with the activity of ciprofloxacin against 5,252 clinical bacterial isolates
22. Therapy with newer oral β-lactam and quinolone agents for infections of the skin and skin structures: a review
23. Ofloxacin versus parenteral therapy for chronic osteomyelitis
24. Use of fluoroquinolones in children: an overview
25. Lomefloxacin vs amoxicillin in patients with acute exacerbations of chronic bronchitis: a UK multicentre study
26. In vitro activities of five quinolones against Chlamydia pneumoniae
27. Genetische Grundlagen und Verbreitung von Fluorochinolonresistenz
28. Effect of method, medium, pH and inoculum on the in-vitro antibacterial activities of fleroxacin and norfloxacin
29. Fluoroquinolone antimicrobial agents
30. Mechanisms of action of and resistance to ciprofloxacin
31. Therapy of gastrointestinal, central nervous system, and bone infections with new quinolones
32. Overview of the fluoroquinolone antibiotics
33. In vitro activity of AT-4140 against clinical bacterial isolates
34. Tolerability of ciprofloxacin in pediatric patients with cystic fibrosis
35. Ofloxacin pharmacokinetics in chronic renal failure and dialysis
36. Quinolones, infective endocarditis, septicaemia, infections of the respiratory tract; meningitis; infections of the alimentary tract
37. Fluoroquinolones in the treatment of cystic fibrosis: a critical appraisal
38. Comparison of intravenous followed by oral ciprofloxacin and intravenous ceftazidime in the treatment of lower respiratory infections
39. Mycobacteria and the new quinolones
40. Management of institutional outbreaks of salmonella gastroenteritis
41. Pefloxacin in acute exacerbations of chronic bronchitis
42. Use of quinolones in the immunocompromised host
43. Randomised comparison of oral ofloxacin alone and with combination of parenteral antibiotics in neutropenic febrile patients
44. Role of quinolones in surgical prophylaxis
45. Analysis of acquired ciprofloxacin resistance in a clinical strain of Pseudomonas aeruginosa
46. Quinolones and the immune system
47. Role of the quinolones in the treatment of legionellosis
48. Sexually transmitted diseases
49. Pharmacokinetics of fluoroquinolones in hepatic failure
50. Assessment of adverse events during drug development: experience with temafloxacin
51. Lomefloxacin versus norfloxacin versus ciprofloxacin in the treatment of complicated urinary tract infections
52. Synergy and antagonism of combinations with quinolones
53. Quinolones and cutaneous disease
54. Therapeutic failure and selection of resistance in a case of pneumococcal pneumonia treated with ciprofloxacin
55. Passage of three newer quinolones in the human breast milk and the amniotic fluid
56. Treatment of typhoid fever and infectious diarrhoea with ciprofloxacin
57. Interactions, of fluoroquinolones: mechanisms, variability, clinical significance, and management
58. An economic assessment of ofloxacin
59. A worldwide clinical overview of lomefloxacin, a once-daily fluoroquinolone
60. Quinolone pharmacokinetics
61. Major change in the structure and morphology of the bacterial nucleotide after treatment of cells with quinolones
62. Chlamydial infections and the quinolones
63. Clinical and laboratory experience with ciprofloxacin in children two to sixteen years of age
64. Quinolones and sexually transmitted diseases
65. Lomefloxacin versus ciprofloxacin in the treatment of complicated or recurrent UTI
66. Toxicity of quinolones in pediatric patients
67. Pharmacokinetics and tissue penetration of quinolones
68. The use of quinolones in children — toxi-cological aspects
69. Oral ofloxacin therapy of infections due to multiply-resistant bacteria
70. Lomefloxacin versus trimethoprim/sulfamethoxazole in the treatment of adults with acute bacterial diarrhea
71. Clinical pharmacokinetics of Sparfloxacin
72. Urinary tract infections
73. Mode of action of quinolones: antibacterial aspects
74. Quinolones in children
75. Fleroxacin clinical pharmacokinetics
76. Effect of a new quinolone, sparfloxcin, on the pharmacokinetics of theophylline in asthmatic patients
77. Ofloxacin: a reappraisal of its antimicrobial activity, pharmacology and therapeutic use
78. Pseudomonas aeruginosa: in vitro susceptibility to antimicrobial drugs, single and combined, with and without defibrinated human blood
79. Response of legionellosis infection to ciprofloxacin in critically ill patients
80. Synergistic, additive, and antagonistic activity of antimicrobial agents: how to measure? What are the clinical consequences? Applications to the new fluoroquinolones
81. Using quinolones in urinary tract infections in children
82. In vitro activity of ciprofloxacin: an overview
83. Lomefloxacin: a review of its antibacterial activity, pharmacokinetic properties and therapeutic use
84. The fluoroquinolones
85. Brief report. Effects of ciprofloxacin on plasmids
86. Structure-activity relationships of fluoroquinolones
87. Overview of fluoroquinolone safety
88. Pharmacokinetics of quinolones: newer aspects
89. Lomefloxacin versus amoxicillin in the treatment of acute exacerbations of chronic bronchitis: results of multinational studies
90. Use of nonlinear mixed-effects modeling for population analysis of ofloxacin effects of age on oral drug pharmacokinetics